Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Breast cancer remains a significant health challenge globally with approximately 2.3M new cases in 2022. While breast cancer ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

ICL (TASE: ICL: NYSE: ICL) led the market today, falling 3.7% on the day's biggest trading turnover, after publishing disappointing fourth quarter results, while parent company Israel Corp. (TASE: ...

The pharmaceutical company expects the expansion will create thousands of jobs.

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...